Determination and pharmacokinetic study of Enasidenib in rat plasma by UPLC–MS/MS

摘要

Enasidenib, an oral product for treating Acute Myeloid Leukemia, has been approved by FDA in Aug, 2017. In this study, we set up an ultra-performance liquid chromatography-mass spectrometry (UPLC-MS/MS) method for measuring Enasidenib and imatinib (internal standard, IS), simultaneously. Enasidenib and imatinib were separated on an ACQUITY UPLC BEH C18Column (2.1?mm?×?50?mm, 1.7?μm, 132??). Mass detection was carried out by electrospray ionization in the position mode, and the multiple reaction monitoring transitions werem/z?474.23?→?456.17 andm/z?494.30?→?394.20 for Enasidenib and imatinib, respectively. Linearity (2???500?ng·mL?1, R2?>?0.999), precision and accuracy (RE?